vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Kosmos Energy Ltd.（KOS）财务数据对比。点击上方公司名可切换其他公司
Kosmos Energy Ltd.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.9倍（$294.6M vs $152.6M），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -25.9%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -16.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
科斯莫斯能源是一家美国上游石油企业，总部位于得克萨斯州达拉斯。公司目前在加纳、赤道几内亚近海以及墨西哥湾开展油气生产与开发业务，在毛里塔尼亚、塞内加尔近海拥有开发项目，还在纳米比亚、圣多美和普林西比、苏里南近海持有勘探许可。
CPRX vs KOS — 直观对比
营收规模更大
KOS
是对方的1.9倍
$152.6M
营收增速更快
CPRX
高出33.5%
-25.9%
两年增速更快
CPRX
近两年复合增速
-16.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $294.6M |
| 净利润 | $52.7M | — |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | -125.7% |
| 净利率 | 34.5% | — |
| 营收同比 | 7.6% | -25.9% |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | $-0.80 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXKOS
| Q4 25 | $152.6M | $294.6M | ||
| Q3 25 | $148.4M | $311.0M | ||
| Q2 25 | $146.6M | $392.6M | ||
| Q1 25 | $141.4M | $290.1M | ||
| Q4 24 | $141.8M | $397.6M | ||
| Q3 24 | $128.7M | $407.8M | ||
| Q2 24 | $122.7M | $447.8M | ||
| Q1 24 | $98.5M | $422.3M |
净利润CPRXKOS
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $-124.3M | ||
| Q2 25 | $52.1M | $-87.7M | ||
| Q1 25 | $56.7M | $-110.6M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $45.0M | ||
| Q2 24 | $40.8M | $59.8M | ||
| Q1 24 | $23.3M | $91.7M |
毛利率CPRXKOS
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
营业利润率CPRXKOS
| Q4 25 | 40.5% | -125.7% | ||
| Q3 25 | 44.7% | -34.2% | ||
| Q2 25 | 45.2% | -16.2% | ||
| Q1 25 | 44.8% | -32.4% | ||
| Q4 24 | 44.3% | -8.5% | ||
| Q3 24 | 39.6% | 26.1% | ||
| Q2 24 | 44.2% | 30.2% | ||
| Q1 24 | 27.5% | 33.6% |
净利率CPRXKOS
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | -40.0% | ||
| Q2 25 | 35.6% | -22.3% | ||
| Q1 25 | 40.1% | -38.1% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 11.0% | ||
| Q2 24 | 33.2% | 13.3% | ||
| Q1 24 | 23.6% | 21.7% |
每股收益（稀释后）CPRXKOS
| Q4 25 | $0.40 | $-0.80 | ||
| Q3 25 | $0.42 | $-0.26 | ||
| Q2 25 | $0.41 | $-0.18 | ||
| Q1 25 | $0.45 | $-0.23 | ||
| Q4 24 | $0.44 | $0.00 | ||
| Q3 24 | $0.35 | $0.09 | ||
| Q2 24 | $0.33 | $0.12 | ||
| Q1 24 | $0.19 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $91.5M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $954.3M | $528.6M |
| 总资产 | $1.1B | $4.7B |
| 负债/权益比越低杠杆越低 | — | 5.78× |
8季度趋势，按日历期对齐
现金及短期投资CPRXKOS
| Q4 25 | $709.2M | $91.5M | ||
| Q3 25 | $689.9M | $64.0M | ||
| Q2 25 | $652.8M | $51.7M | ||
| Q1 25 | $580.7M | $49.8M | ||
| Q4 24 | $517.6M | $85.0M | ||
| Q3 24 | $442.3M | $51.6M | ||
| Q2 24 | $375.7M | $173.8M | ||
| Q1 24 | $310.4M | $254.3M |
总债务CPRXKOS
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CPRXKOS
| Q4 25 | $954.3M | $528.6M | ||
| Q3 25 | $920.2M | $898.8M | ||
| Q2 25 | $856.0M | $1.0B | ||
| Q1 25 | $794.3M | $1.1B | ||
| Q4 24 | $727.6M | $1.2B | ||
| Q3 24 | $660.9M | $1.2B | ||
| Q2 24 | $608.7M | $1.1B | ||
| Q1 24 | $561.4M | $1.1B |
总资产CPRXKOS
| Q4 25 | $1.1B | $4.7B | ||
| Q3 25 | $1.1B | $5.1B | ||
| Q2 25 | $971.9M | $5.2B | ||
| Q1 25 | $908.9M | $5.3B | ||
| Q4 24 | $851.4M | $5.3B | ||
| Q3 24 | $772.0M | $5.5B | ||
| Q2 24 | $706.4M | $5.4B | ||
| Q1 24 | $646.7M | $5.4B |
负债/权益比CPRXKOS
| Q4 25 | — | 5.78× | ||
| Q3 25 | — | 3.31× | ||
| Q2 25 | — | 2.80× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $35.3M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXKOS
| Q4 25 | $44.9M | $35.3M | ||
| Q3 25 | $32.4M | $-27.6M | ||
| Q2 25 | $71.3M | $127.2M | ||
| Q1 25 | $60.0M | $-888.0K | ||
| Q4 24 | $70.9M | $175.7M | ||
| Q3 24 | $72.9M | $6.3M | ||
| Q2 24 | $64.1M | $223.7M | ||
| Q1 24 | $31.9M | $272.6M |
自由现金流CPRXKOS
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.7M | — |
自由现金流率CPRXKOS
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — | ||
| Q1 24 | 32.2% | — |
资本支出强度CPRXKOS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率CPRXKOS
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 0.14× | ||
| Q2 24 | 1.57× | 3.74× | ||
| Q1 24 | 1.37× | 2.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
KOS
| Ghana Segment | $134.6M | 46% |
| Gulf Of America | $80.7M | 27% |
| Mauritania And Senegal | $54.9M | 19% |
| Equatorial Guinea Segment | $24.3M | 8% |
